Spartalizumab (INN;[1] development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma.
This drug is being developed by Novartis. As of 2018[update], spartalizumab is undergoing Phase III trials.[2]
^World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
^Kaplon H, Muralidharan M, Schneider Z, Reichert JM (2020). "Antibodies to watch in 2020". mAbs. 12 (1): 1703531. doi:10.1080/19420862.2019.1703531. PMC 6973335. PMID 31847708.
Spartalizumab (INN; development code PDR001) is a monoclonal antibody and checkpoint inhibitor that is being investigated for melanoma. This drug is being...
with spartalizumab (PDR001), an anti-PD-1 monoclonal antibody has been completed. Recruiting for a phase 2 study in combination with spartalizumab for...
approved to treat melanoma and lung cancer and is produced by Merck. Spartalizumab (PDR001) is a PD-1 inhibitor being developed by Novartis to treat both...
effects. Specific drugs being tested are atezolizumab, pembrolizumab, and spartalizumab, amongst others. Combinatorial therapy that is molecular-based may lead...
Global Information